Methyl L-tryptophanate hydrochloride (L-tryptophan methyl ester hydrochloride, H-Trp-OMe·HCl, CAS: 7524-52-9) is a chiral α-amino acid ester derivative of the essential amino acid tryptophan, with the molecular formula C₁₂H₁₅ClN₂O₂ and molecular weight 254.71 g/mol. Its structure comprises a methyl ester-protected L-tryptophan backbone featuring an indole side chain (C₈H₆N)—a large, π-rich aromatic heterocycle that is highly susceptible to hydrogen‑bonding, hydrophobic stacking, and metal‑coordination interactions in biological systems. The addition of the hydrochloride salt significantly improves the compound’s stability and water solubility, preventing the hydrolysis of the free methyl ester that would otherwise occur under ambient conditions. This unique architecture combines a chiral center (critical for stereoselective synthesis), a chemically modifiable ester group (enabling peptide chain elongation or reduction to the corresponding alcohol), and an indole ring that participates in π‑π stacking, cation‑π interactions, and enzyme recognition. As the most widely applied carboxylic‑protected form of tryptophan, methyl L-tryptophanate hydrochloride plays an indispensable role across multiple high‑value sectors: it serves as a key monomer in solid‑phase peptide synthesis (SPPS) for incorporating tryptophan residues into bioactive peptide sequences; it is a crucial intermediate in the synthesis of central nervous system (CNS) drugs, including certain antidepressants (selective serotonin reuptake inhibitors), anxiolytics, and sedatives; it is a reference standard in analytical method development (HPLC, LC‑MS) for the quantitation of tryptophan and its metabolites in biological matrices; it is a valuable tool in biochemical studies of indoleamine metabolism (particularly the kynurenine pathway and serotonin biosynthesis) and in enzyme assays targeting tryptophan hydroxylase (TPH), indoleamine 2,3‑dioxygenase (IDO), and tryptophanyl‑tRNA synthetase; and it serves as a precursor for the synthesis of the amino acid amide L‑tryptophanamide hydrochloride, a compound used in investigations of neuropeptide function. Its production typically involves Fischer esterification of L‑tryptophan with methanol under acid catalysis (with strict temperature control at 0–5°C to prevent racemization), followed by isolation of the dihydrochloride salt via cooling crystallization—a process virtually identical to that used for the parallel compound methyl L‑histidinate dihydrochloride. With the global peptide therapeutic market projected to exceed USD 50–55 billion by 2030, and with tryptophan’s unique indole side chain being essential for the activity of numerous neuroactive peptides, oncolytic agents, and antimicrobial peptides, the demand for high‑purity methyl L‑tryptophanate hydrochloride continues to expand steadily. Based on its chemical characteristics and industrial chain position, this article systematically analyzes international market dynamics of this compound, focusing on core application scenarios, competitive landscape, regional differences, regulatory trends, and future outlook, providing strategic references for industry participants.
Core Application Fields and Demand
Market demand for methyl L‑tryptophanate hydrochloride is highly concentrated in four major areas: peptide synthesis & pharmaceutical intermediate development (≈45% of global consumption), central nervous system (CNS) drug discovery (≈25%), biochemical & indoleamine metabolism research (≈20%), and analytical reference standards (≈10%). Its chiral purity and indole functionality drive widespread adoption.
In peptide synthesis and pharmaceutical research, H‑Trp‑OMe·HCl is highly valued as a carboxylic‑protected building block that allows the efficient incorporation of tryptophan residues into peptide chains via solid‑phase peptide synthesis (SPPS), using either the Fmoc or Boc strategy. It is a key reactant in the multistep construction of neuropeptides (such as substance P, neurotensin, orexin/hypocretin), oncolytic peptides (host‑defense peptides that target cancer cells), antimicrobial peptides (including certain defensins and cathelicidins), and integrin‑binding peptide motifs (RGD‑like sequences where tryptophan residues are essential for conformational stability). The compound is also employed in the synthesis of tryptophan‑rich “cell‑penetrating peptides” (CPPs) that enhance the intracellular delivery of therapeutic cargos, and as a chiral starting material for the construction of unnatural tryptophan analogs via indole C–H functionalization. The global peptide therapeutics market, growing at 6‑8% annually, is the primary driver of demand for high‑purity amino acid derivatives.
In central nervous system (CNS) drug discovery, methyl L‑tryptophanate hydrochloride serves as a key intermediate in the synthesis of tryptophan‑derived pharmacological agents, including selective serotonin reuptake inhibitors (SSRIs) and other antidepressants, anxiolytics (agents that reduce anxiety without sedation), and sedative‑hypnotics (medications that promote sleep). The compound is also used as a chiral precursor in the synthesis of tadalafil impurities (e.g., tadalafil impurity 14) and other phosphodiesterase‑5 (PDE5) inhibitors. The global CNS drug market, which includes treatments for depression, anxiety disorders, insomnia, schizophrenia, Parkinson’s disease, and Alzheimer’s disease, is projected to grow at a CAGR of 5‑6% over the next five years, creating sustained demand for high‑purity, enantiomerically pure tryptophan derivatives.
In biochemical research, methyl L‑tryptophanate hydrochloride is widely used as a substrate in enzyme assays, primarily for studying the enzyme kinetics and mechanisms of tryptophan‑modifying enzymes such as tryptophan hydroxylase (TPH, the rate‑limiting enzyme in serotonin biosynthesis), indoleamine 2,3‑dioxygenase (IDO, an immunomodulatory enzyme that catalyzes the first step of the kynurenine pathway), and tryptophanyl‑tRNA synthetase (TrpRS, the enzyme that attaches tryptophan to its cognate tRNA during protein synthesis). The compound’s methyl ester group allows it to penetrate cell membranes more readily than free tryptophan, making it a useful probe for studying intracellular indoleamine metabolism, the kynurenine pathway’s role in neuroinflammation and depression, serotonin biosynthesis in enterochromaffin cells, and the cross‑talk between the immune system and neurotransmitter production. In the pharmaceutical industry, H‑Trp‑OMe·HCl is also used as a standard reference compound for HPLC and LC‑MS method validation, enabling accurate quantitation of tryptophan and its metabolites in cerebrospinal fluid (CSF), plasma, urine, and tissue homogenates.
Major Market Participants
The global supply system for methyl L‑tryptophanate hydrochloride follows the well‑established pattern of “specialized fine chemical and peptide building block manufacturers, primarily in North America, Europe, China, and India, serving both small‑scale R&D customers and large‑scale industrial peptide synthesis facilities.” The compound is commonly supplied as a white to off‑white crystalline powder with purity ranging from 97% to ≥99% by HPLC, with typical specifications including a melting point of 218–220°C (a sharp melting range confirms both purity and crystalline homogeneity), specific optical rotation [α]²⁰ᴰ = +17° to +19° (c=5 in methanol), and moisture content <0.5%. Factors that distinguish market participants include the ability to offer validated enantiomeric purity (ensuring the L‑configuration and preventing side reactions in stereospecific couplings), cGMP‑compliant documentation for pharmaceutical applications (including DMF support for generic peptide API registration with the US FDA), and flexible packaging from bulk kilogram scale for industrial SPPS runs to smaller gram quantities for academic research and medicinal chemistry screening.
Shanghai XinChem Co., Ltd. (XinChem) has established a reliable, quality‑controlled supply chain for high‑purity methyl L‑tryptophanate hydrochloride. Our product meets rigorous specifications—purity ≥98% to ≥99% (HPLC), white to off‑white crystalline powder, melting point 218–220°C, specific optical rotation within the accepted range, controlled residual solvents, and strict heavy metal limits—fully complying with global peptide synthesis standards, CNS drug intermediate requirements, and biochemical research specifications. As the global market for methyl L‑tryptophanate hydrochloride was valued at approximately USD 0.015 million in 2024 and is projected to reach USD 0.027 million by 2033, corresponding to a CAGR of 5.7% during the 2026‑2033 period, XinChem is well‑positioned to serve the growing demand from peptide API manufacturers, contract research organizations (CROs), and academic research institutions.
Regional Market Dynamics
Global demand for methyl L‑tryptophanate hydrochloride shows regional differentiation: “North America and Europe lead in pharmaceutical R&D, peptide‑based drug development, and CNS drug discovery; Asia‑Pacific dominates contract research and manufacturing (CRO/CDMO) and is the fastest‑growing region for intermediate supply; and Latin America & Middle East/Africa follow as emerging research hubs with increasing biotech investments.”
North America (United States + Canada) accounts for approximately 35–40% of global demand, driven by a robust biopharmaceutical sector, an extensive pipeline of peptide drug candidates (including GLP‑1 agonists for diabetes and obesity, and neuropeptide analogs for CNS disorders), strong academic life science research funding from the NIH and private foundations, and the presence of major peptide API manufacturers. Regulatory documentation (COA, enantiomeric purity certificates, residual solvents analysis, DMF support) and strict compliance with FDA guidelines (21 CFR Parts 210/211, cGMP) and USP/NF monographs are required for all customers placing materials into Phase II/III clinical trials or commercial peptide products.
Europe constitutes approximately 30–35% of global demand, with Germany (a powerhouse of medicinal chemistry and peptide drug discovery), Switzerland (home to several major pharmaceutical companies with large peptide portfolios), the United Kingdom (a leader in neuropeptide research and biotech startups), and France being major consumers. The region‘s strong peptide therapeutics industry, advanced neuroscience research programs, and strict adherence to REACH regulations (EC 1907/2006) push suppliers to maintain rigorous documentation standards, including full data on residual solvents, genotoxic impurities, and heavy metals. The European Medicines Agency’s (EMA) emphasis on the validation of chiral purity and product consistency for peptide synthesis intermediates for use in clinical trials is particularly pronounced, and customers increasingly require evidence of the absence of pyrogens and endotoxins for parenteral peptide formulations.
Asia‑Pacific is the fastest‑growing market for methyl L‑tryptophanate hydrochloride, increasing at a CAGR of approximately 7–9%. China has emerged as a dominant manufacturing hub for fine chemical intermediates and peptide building blocks, with cost‑competitive production (labor, raw materials, utilities) and comprehensive supply chain integration (from basic organic synthesis to multi‑ton SPPS). Major growth drivers include significant government investment in biotechnology and peptide pharmaceutical innovation (including the “Made in China 2025” and “Healthy China 2030” initiatives), the rapid expansion of CRO/CDMO service providers (who are increasingly responsible for the synthesis of peptide drugs destined for Western markets), and increasing domestic demand for research reagents as China’s life sciences sector matures. Japan and South Korea also demand high‑purity grades for their advanced peptide and CNS drug development programs, as well as for certain applications in the electronics‑adjacent biochemical and semiconductor cleaning sectors.
Regulatory and Environmental Considerations
Methyl L‑tryptophanate hydrochloride (CAS 7524-52-9) is a compound that must meet stringent quality standards for pharmaceutical research and peptide intermediate use. The compound is classified as Xi (Irritant) with the risk phrase R36/37/38 (irritating to eyes, respiratory system, and skin) and is labeled with safety precautions S22 (do not breathe dust) and S24/25 (avoid contact with skin and eyes). The hazard classification is based on the potential for skin/respiratory irritation and serious eye injury upon repeated or prolonged exposure in powder form. The compound is not classified as carcinogenic or mutagenic, it lacks acute toxicity reports at normal handling levels (LD₅₀ data are sparse but the free amino acid tryptophan is considered GRAS), and it is not considered a marine pollutant. The hydrochloride salt is hygroscopic and requires storage under a dry, inert atmosphere (nitrogen or argon) at 2–8°C in tightly sealed, light‑resistant (amber glass or opaque plastic) containers, away from strong oxidizing agents and strong bases. The material is stable for up to 24 months when stored in powder form under these conditions.
In the European Union, methyl L‑tryptophanate hydrochloride is subject to REACH regulations (EC 1907/2006) as a research chemical rather than a registered industrial intermediate in large volumes; however, importers and manufacturers who place ≥1,000 kg of the substance on the EU market per annum must register the material with the European Chemicals Agency (ECHA). Suppliers must provide Safety Data Sheets (SDS) that include full exposure controls and personal protective equipment (PPE) recommendations, and must label the substance according to CLP standards (EC 1272/2008) with Xi hazard classification (Eye Irrit. 2, Skin Irrit. 2, STOT SE 3). Transport is regulated under ADR/RID for road/rail and IMDG for sea, with the substance classified as a non-flammable, non‑toxic solid (Class 9, Packaging Group III for most formulations).
In the United States, the EPA regulates methyl L‑tryptophanate hydrochloride under the Toxic Substances Control Act (TSCA) as a research chemical (TSCA inventory status: listed). Import shipments are subject to routine compliance review by US Customs and Border Protection (CBP). No specific FDA monograph exists for this intermediate; however, its use in the synthesis of pharmaceutical APIs (both small molecule and peptide active ingredients) must adhere to cGMP guidelines (21 CFR Parts 210/211) and ICH Q7 quality standards, including the full documentation of impurity profiles, residual solvents (ICH Q3C), and heavy metals (ICH Q3D).
In China, methyl L‑tryptophanate hydrochloride is listed in the Inventory of Existing Chemical Substances (IECSC) and must comply with GB standards (GB/T 34756-2017 for amino acid derivatives). Safety production licenses are required for manufacturing facilities, and the Ministry of Ecology and Environment (MEE) sets discharge limits for organic nitrogen‑containing waste streams (notably indole‑containing effluents). The compound is assigned customs HS Code 29339900 (heterocyclic compounds with nitrogen hetero‑atom(s) only) or, more specifically, HS Code 29332900 (compounds containing an unfused imidazole ring, though this may require clarification with the importer’s customs broker). The Chinese Pharmacopoeia (ChP) monograph for tryptophan amino acid derivatives may be used for quality release by domestic manufacturers.
Environmentally, methyl L‑tryptophanate hydrochloride is classified as readily biodegradable (OECD 301 B/C), with no anticipated bioaccumulation potential and negligible aquatic toxicity at expected environmental release levels (EC₅₀ >100 mg/L for most aquatic organisms). Manufacturing generates waste streams containing methanol and hydrochloric acid (both of which can be neutralized and treated in conventional biological wastewater treatment plants with proper pH adjustment), along with indole‑containing organic by‑products that require responsible disposal (typically incineration, as indole derivatives can be resistant to complete degradation in conventional activated sludge systems). Green chemistry efforts focus on the Fischer esterification with methanol recovery (via distillation) and solvent recycling (methanol and ethyl acetate), as well as the development of continuous flow esterification processes that reduce energy consumption, improve heat management (which is critical for controlling racemization), and minimize waste generation.
Future Outlook
The market outlook for methyl L‑tryptophanate hydrochloride is tied to four core drivers: (1) the rapid expansion of the global peptide therapeutics market, with GLP‑1 agonists (such as semaglutide and tirzepatide) and neuropeptide analogs for CNS disorders leading the way—a market projected to reach USD 50–55 billion by 2030; (2) increasing research on indoleamine metabolism, the kynurenine pathway’s role in neuroinflammation and depression, and IDO/TPH inhibitors for cancer immunotherapy and mood disorders; (3) the growth of the contract research and manufacturing services sector (CRO/CDMO) in Asia‑Pacific, particularly in China and India, where manufacturing costs are approximately 30–40% lower than in Western Europe or North America; and (4) rising investments in life sciences and peptide drug innovation by academic and government institutions in emerging economies. The global market for methyl L‑tryptophanate hydrochloride is projected to grow at a CAGR of 5.7% over the period 2026‑2033, from a value of USD 0.015 million in 2024 to USD 0.027 million by 2033.
On the demand side, the peptide API manufacturing sector will be the largest and fastest‑growing driver, fueled by the approval of new peptide‑based drugs for diabetes (GLP‑1 agonists), obesity, and oncology (oncolytic peptides, such as those that disrupt cancer cell membranes or target intracellular proteins). Research into the kynurenine pathway and its role in the pathogenesis of neurodegenerative disorders (Parkinson’s, Alzheimer’s, Huntington’s) and major depression continues to expand, creating new demand for high‑purity tryptophan derivatives as substrates in enzyme assays and as metabolic probes. The expansion of academic research and government‑funded life science initiatives in Asia‑Pacific (including the Chinese Academy of Sciences’ “Strategic Priority Research Programs” and India’s “Biotechnology Industry Partnership Programme”) will drive steady growth in demand for research‑grade H‑Trp-OMe·HCl at the gram‑to‑kilogram scale.
Challenges include: raw material cost dependence on L‑tryptophan supply, which is sourced either from fermentation (using genetically engineered E. coli or Corynebacterium glutamicum) or from protein hydrolysis (of casein, albumin, or soy protein), and is therefore subject to fluctuations in agricultural commodity prices (particularly for soy and corn, the feedstocks for fermentation processes) and currency exchange rates; competition from newer tryptophan derivatives offering alternative protection strategies (Fmoc-Trp-OMe, Boc-Trp-OMe) for different SPPS protocols (these selectively protected building blocks are more expensive and are used only in the final steps of complex peptide syntheses); and the need for stringent dry storage conditions (under inert atmosphere, low temperature, and low humidity) to prevent hydrolysis of the methyl ester (which would generate free tryptophan and render the building block unsuitable for SPPS), which limits certain distribution channels and requires cold‑chain logistics.
Enterprises should focus on providing validated chiral purity (≥99% enantiomeric excess, with documentation of the analytical method used, such as chiral HPLC), DMF‑ready documentation for peptide API developers (including the full synthesis description, impurity profiles, residual solvents, and heavy metals), ensuring cold‑chain integrity for global distribution (with real‑time temperature logging and qualified shipping containers for tropical destinations), and building long‑term supply partnerships with peptide API manufacturers (multinational and generic), contract research organizations (CROs), and academic research institutions.
Shanghai XinChem Co., Ltd. (XinChem)
As a world‑leading supplier of organic chemicals, chiral intermediates, and peptide synthesis building blocks, Shanghai XinChem Co., Ltd. (XinChem) has always focused on the innovative needs of the peptide API manufacturing, CNS drug discovery, and pharmaceutical research industries. Relying on core technological advantages in chiral amino acid derivative synthesis, esterification process control, and rigorous quality assurance, we provide high‑purity methyl L‑tryptophanate hydrochloride (L‑tryptophan methyl ester hydrochloride, H-Trp-OMe·HCl, CAS: 7524-52-9) to global customers. Our product is manufactured under strict quality management systems, achieving consistent purity ≥98% to ≥99% (by HPLC), white to off‑white crystalline powder appearance, controlled optical rotation ([α]²⁰ᴰ = +17° to +19°, c=5 in methanol), sharp melting point (218–220°C), low residual solvents (<0.5% total), and extremely low heavy metals (Pb, As, Cd, Hg each ≤10 ppm, meeting ICH Q3D guidelines), fully complying with global peptide synthesis, CNS drug intermediate, and biochemical research standards. It is an ideal chiral indole building block for the synthesis of peptide therapeutics (including GLP‑1 analogs, neuropeptides, oncolytic peptides, and cell‑penetrating peptides), CNS drug intermediates (antidepressants, anxiolytics, sedatives), tryptophan metabolite reference standards, and enzyme substrates for indoleamine metabolism research.
1. Technical Advantages
- High Chiral Purity & Enantiomeric Excess: Our methyl L‑tryptophanate hydrochloride achieves purity ≥98% to ≥99% (by HPLC, area%). Both the chemical purity and the enantiomeric purity (L‑configuration) are verified by validated HPLC and TLC methods, ensuring stereospecific performance in SPPS, preventing the incorporation of mirror‑image D‑tryptophan isomers that would produce biologically inactive or immunogenic peptides. The product’s specific optical rotation [α]²⁰ᴰ = +17° to +19° (c=5 in methanol) confirms the L‑configuration, and an enantiomeric excess (ee) of ≥99% is guaranteed. Independent third‑party chiral chromatograms are available upon request.
- Low Impurity Profile & Rigorous Stability Testing: The product is supplied as a stable, white to off‑white crystalline powder (melting point 218–220°C), fully soluble in methanol, ethanol, DMSO, and water, and in standard peptide synthesis solvents (DMF, NMP, DCM). We maintain strict control over residual solvents (<0.5% total, ICH Q3C Class 2 and Class 3 limits), heavy metals (Pb, As, Cd, Hg each ≤10 ppm, tested by ICP‑MS), and water content (Karl Fischer titration, <0.5%). The material is also tested for the absence of any indole oxidation products (SDS‑PAGE, TLC) and any side‑products resulting from incomplete esterification, ensuring maximal coupling efficiency and minimal by‑product formation in SPPS cycles.
- Batch‑to‑Batch Consistency: All production lots are tested against our rigid quality control protocols, with batch‑to‑batch variation controlled within 0.5% for HPLC purity, 0.2°C for melting point, and ±0.5 degrees for specific optical rotation, ensuring reliable, reproducible results for customers running validated peptide synthesis protocols, including those in cGMP environments for clinical‑scale or commercial production of peptide therapeutics.
2. Product Advantages
- Versatile Chiral Indole Synthon: Widely used in solid‑phase peptide synthesis (SPPS), the synthesis of tryptophan‑rich cell‑penetrating peptides (CPPs), the construction of unnatural tryptophan analogs via indole C–H functionalization (Palladium‑catalyzed, photoredox, or enzymatic), the production of CNS drug intermediates (antidepressants, anxiolytics), and as a substrate in the study of indoleamine 2,3‑dioxygenase (IDO) and tryptophan hydroxylase (TPH, EC 1.14.16.4) enzyme kinetics. The methyl ester group also allows facile conversion to the corresponding alcohol (via reduction with LiBH₄ or NaBH₄ in THF), providing access to tryptophanol derivatives that are valuable as chiral auxiliaries in asymmetric synthesis.
- Superior Solubility & Chemical Stability: Soluble in a wide range of organic solvents (DMSO: 25 mg/mL ≈ 98.1 mM; methanol and ethanol ≥50 mg/mL; DMF and NMP ≥100 mg/mL) and in water (≈10 mg/mL), fully compatible with standard peptide synthesis workflows. The hydrochloride salt form provides significantly improved stability during storage and prevents the hydrolysis of the methyl ester group that would otherwise occur with the free base. Storage under inert atmosphere (argon or nitrogen) at 2–8°C in the original tightly sealed container is recommended, and the material is stable for up to 24 months when handled under these conditions. For long‑term archiving (>2 years) of reference standards, storage at −20°C is recommended.
- High Coupling Efficiency in SPPS: When used as the building block for tryptophan incorporation in either Fmoc‑ or Boc‑based SPPS, our H‑Trp-OMe·HCl consistently delivers coupling yields of ≥95%, as measured by the Kaiser test (ninhydrin assay) for resin‑bound primary amines, with minimal epimerization (≤0.5%) due to careful control of the esterification and isolation conditions.
- Flexible Packaging & Cold‑Chain Support: Available in 5g, 10g, 25g, 50g, 100g, 500g glass or HDPE bottles (for R&D and medicinal chemistry screening), 1 kg HDPE containers (for pilot studies), and 5 kg, 10 kg, 25 kg fiber drums (for industrial‑scale peptide manufacturing). Full custom packaging and cold‑chain logistics (2–8°C shipment, with qualified thermal shippers and real‑time temperature monitoring for tropical destinations) are available upon request.
- Reliable Supply Chain & Large‑Scale Capacity: Annual production capacity is 10–50 metric tons, with dedicated cold‑chain warehousing (2–8°C, nitrogen blanket in headspace, humidity‑controlled at ≤30% RH) and just‑in‑time delivery capabilities. XinChem maintains a multi‑ton safety stock of both L‑tryptophan starting material and the finished methyl ester hydrochloride, allowing us to respond rapidly to urgent orders for CDMOs and peptide API manufacturers.
3. Application Fields
- Peptide Synthesis & Pharmaceutical Intermediates: Solid‑phase peptide synthesis (SPPS, both Fmoc and Boc strategies) for GLP‑1 analogs (e.g., semaglutide, liraglutide), neuropeptides (substance P, neurotensin, orexin/hypocretin), oncolytic peptides (host‑defense peptides such as LTX‑315, those disrupting cancer cell membranes), cell‑penetrating peptides (TAT, Penetratin, Arg/Lys‑rich CPPs with tryptophan residues), and integrin‑binding peptide motifs (RGD‑like sequences, where a tryptophan residue is essential for bioactivity). It is also used in the synthesis of tadalafil impurities and other PDE5 inhibitors.
- Central Nervous System (CNS) Drug Intermediates: Key intermediate in the synthesis of selective serotonin reuptake inhibitors (SSRIs), including certain antidepressants that feature a tryptophan‑derived scaffold; anxiolytics (agents that reduce anxiety without sedation); sedative‑hypnotics (medications that promote sleep); and other CNS drugs acting on serotonergic, dopaminergic, or melatonin receptors. The compound also serves as a precursor for the synthesis of tryptamine derivatives, some of which are pharmaceutical intermediates in their own right.
- Biochemical & Indoleamine Metabolism Research: Substrate for enzyme assays targeting tryptophan hydroxylase (TPH1 and TPH2, the rate‑limiting enzymes in serotonin biosynthesis, EC 1.14.16.4), indoleamine 2,3‑dioxygenase (IDO1, an immunomodulatory enzyme that catalyzes the first and rate‑limiting step of the kynurenine pathway, EC 1.13.11.52), and tryptophanyl‑tRNA synthetase (WARS/TrpRS, the enzyme that attaches tryptophan to its cognate tRNA). An essential tool for studies of the kynurenine pathway’s role in the pathogenesis of neurodegenerative disorders (Parkinson’s, Alzheimer’s, Huntington’s) and major depression; for investigating serotonin biosynthesis in enterochromaffin cells, the gut‑brain axis, and the cross‑talk between the immune system and neurotransmitter production; and for screening of IDO and TPH inhibitors as potential therapeutics.
- Analytical Reference Standards: Standard reference compound for HPLC and LC‑MS method validation, enabling accurate quantitation of tryptophan and its metabolites (kynurenine, kynurenic acid, 3‑hydroxykynurenine, serotonin, 5‑hydroxyindoleacetic acid, melatonin) in cerebrospinal fluid (CSF), plasma, urine, and tissue homogenates. Essential for clinical diagnostics of neuropsychiatric disorders and for pharmacokinetic studies in CNS drug development.
- Chiral Chemistry & Organic Synthesis: Chiral starting material for the synthesis of unnatural tryptophan analogs via indole C–H functionalization (cross‑coupling, arylation, alkylation, halogenation), for the construction of tryptophan‑containing binaphthyl phosphoric acids for asymmetric catalysis, and as a precursor for the synthesis of the L‑tryptophanol chiral auxiliary, which is used in the asymmetric synthesis of β‑amino acids and other building blocks.
4. Service Support
Our experienced technical team provides full impurity profiling (enantiomeric purity by chiral HPLC, residual solvents by GC‑headspace, heavy metals by ICP‑MS), custom purification to achieve ≥99.5% purity (or any specific purity requirement), and complete regulatory support (Certificate of Analysis – COA, Technical Data Sheet – TDS, Safety Data Sheet – MSDS, REACH compliance, TSCA certification, DMF preparation for pharmaceutical customers, ICH Q3C/Q3D documentation). We offer just‑in‑time delivery, cold‑chain logistics with qualified temperature‑controlled shipping solutions, and full supply chain traceability from batch‑to‑batch. Custom synthesis of analog derivatives (such as the D‑enantiomer, D‑tryptophan methyl ester hydrochloride; the N‑Fmoc or N‑Boc protected derivatives; the amidated form H-Trp-NH₂·HCl; or the corresponding alcohol L‑tryptophanol) is available upon request.
5. Why Choose XinChem
- Professionalism: 20+ years in the chiral intermediate, peptide building block, CNS drug intermediate, and pharmaceutical research industry.
- Flexibility: Tailored to customer purity specifications, enantiopurity requirements, custom packaging, and cold‑chain delivery needs.
- Cost‑effectiveness: High quality at competitive prices, supported by integrated in‑house manufacturing and rigorous quality control.
Contact us now to start cooperation!
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: May-11-2026